JP2015523364A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523364A5
JP2015523364A5 JP2015520652A JP2015520652A JP2015523364A5 JP 2015523364 A5 JP2015523364 A5 JP 2015523364A5 JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015523364 A5 JP2015523364 A5 JP 2015523364A5
Authority
JP
Japan
Prior art keywords
thiosulfate
agent
oxoprotective
sepsis
related condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523364A (ja
JP6509112B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049087 external-priority patent/WO2014008273A2/en
Publication of JP2015523364A publication Critical patent/JP2015523364A/ja
Publication of JP2015523364A5 publication Critical patent/JP2015523364A5/ja
Application granted granted Critical
Publication of JP6509112B2 publication Critical patent/JP6509112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520652A 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および/またはその進行のモニタリングのための方法 Expired - Fee Related JP6509112B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261667719P 2012-07-03 2012-07-03
US61/667,719 2012-07-03
US201261691787P 2012-08-21 2012-08-21
US61/691,787 2012-08-21
US201361748698P 2013-01-03 2013-01-03
US61/748,698 2013-01-03
PCT/US2013/049087 WO2014008273A2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Publications (3)

Publication Number Publication Date
JP2015523364A JP2015523364A (ja) 2015-08-13
JP2015523364A5 true JP2015523364A5 (cg-RX-API-DMAC7.html) 2016-08-25
JP6509112B2 JP6509112B2 (ja) 2019-05-08

Family

ID=49882592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520652A Expired - Fee Related JP6509112B2 (ja) 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および/またはその進行のモニタリングのための方法

Country Status (7)

Country Link
US (1) US20150174160A1 (cg-RX-API-DMAC7.html)
EP (1) EP2866565A4 (cg-RX-API-DMAC7.html)
JP (1) JP6509112B2 (cg-RX-API-DMAC7.html)
CN (1) CN104582490A (cg-RX-API-DMAC7.html)
AU (2) AU2013286876B2 (cg-RX-API-DMAC7.html)
CA (1) CA2915793A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014008273A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522519A (ja) * 2018-04-19 2021-08-30 スティッキーセル ピーティーワイ リミテッドStickycell Pty Ltd 感染症の技術分野における白血球補充
US11406607B2 (en) 2018-05-24 2022-08-09 University Of Florida Research Foundation, Inc. Compositions, methods of treatment, and containers including compositions
AU2023312830A1 (en) * 2022-07-27 2025-02-20 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
CA3262374A1 (en) 2022-09-14 2024-03-21 BiognoSYS AG Methods to determine drug target residence time and to select best drug-target candidates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6712802B1 (en) * 1997-11-04 2004-03-30 Charles B. Cairns Metabolic therapy directed at electron transport
EP1063228B1 (en) * 1998-03-09 2005-01-19 Takeda Pharmaceutical Company Limited Cycloalkene derivatives, process for producing the same, and use
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
PL213982B1 (pl) * 2001-07-27 2013-05-31 Nutricia Nv Zastosowanie fosfolipidów, triglicerydów i cholesterolu oraz kompozycja do podawania dojelitowego
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
CA2487866A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
WO2008156671A2 (en) * 2007-06-13 2008-12-24 Jay Pravda Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
AU2004308966A1 (en) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
US9383348B2 (en) * 2008-06-21 2016-07-05 John E. Repine Compositions and methods for treating lung disorders
CN102781461A (zh) * 2009-12-28 2012-11-14 N.V.佩里科恩有限责任公司 局部用酰基谷胱甘肽制剂

Similar Documents

Publication Publication Date Title
Bevc et al. Measurement of breath ammonia for detection of patients with chronic kidney disease
Ren et al. Dynamic change of hydrogen sulfide during global cerebral ischemia–reperfusion and its effect in rats
JP2015523364A5 (cg-RX-API-DMAC7.html)
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
HRP20120743T1 (hr) Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
MX2009013683A (es) Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo.
ATE537450T1 (de) Igfbp2-biomarker
DE602006021768D1 (de) Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
JP2016118568A5 (cg-RX-API-DMAC7.html)
Chan et al. Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome
JP2013100285A5 (cg-RX-API-DMAC7.html)
FR2959414B1 (fr) Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
Kodavanti et al. Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention
MX2024005426A (es) Derivados de 4h-imidazo[1,5-b]pirazol para diagnostico.
WO2016163727A3 (ko) 황화수소 검출용 방사성 프로브
Myszka et al. Sodium hydrosulfide moderately alleviates the hallmark symptoms of Duchenne muscular dystrophy in mdx mice
Kitzberger et al. Severity of organ failure is an independent predictor of intracranial hypertension in acute liver failure
WO2023215880A3 (en) Compositions and methods for gys1 inhibition
EP3851127A4 (en) Composition for detecting hydrogen sulfide or measuring hydrogen sulfide concentration and composition comprising same as effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer
JP2012524884A5 (cg-RX-API-DMAC7.html)
KR102219895B9 (ko) 쯔쯔가무시병 진단용 조성물 및 이를 포함하는 키트
Golanski et al. Revival of PFA-100–how far is it useful for the monitoring of ADP receptor antagonists?
RU2011144028A (ru) Эффекты пероральной композиции против потери костной массы и потери прикрепления
MX348303B (es) Métodos y composiciones para la evaluación de lesión renal utilizando ácido hialurónico.
EP2405275A4 (en) STABILIZER FOR MANAGEMENT TEST, MANAGEMENT TEST WITH STABILITY AND MEASUREMENT KIT WITH MANAGEMENT TEST